Registrational trial of IMO-2125 in PD1 refractory metastatic melanoma.

Trial Profile

Registrational trial of IMO-2125 in PD1 refractory metastatic melanoma.

Planning
Phase of Trial: Phase III

Latest Information Update: 10 Sep 2017

At a glance

  • Drugs IMO 2125 (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Idera Pharmaceuticals
  • Most Recent Events

    • 10 Sep 2017 This trial is expected to begin in this first quarter of 2018, according to an Idera Pharmaceuticals media release.
    • 21 Mar 2017 New trial record
    • 15 Mar 2017 According to an Idera Pharmaceuticals media release, comany expects to conduct a meeting with the US FDA to discuss the plans for this trial in first quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top